Companion Diagnostics in the COVID-19 Era
17 Jun 2020
Companion diagnostics are rising to the forefront of pharmaceutical development and treatment. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes.
Companion diagnostics can also decrease costs by identifying the patient population that will most likely benefit from the therapy and ruling out therapies that are not likely to be effective. This is especially critical given the cost of many new cancer therapies. Companion diagnostics also improve patient outcomes by selectively determining which patients will respond to therapy.
As part of its coverage, this report provides data and business planning resources for the industry.
Companion diagnostics can also decrease costs by identifying the patient population that will most likely benefit from the therapy and ruling out therapies that are not likely to be effective. This is especially critical given the cost of many new cancer therapies. Companion diagnostics also improve patient outcomes by selectively determining which patients will respond to therapy.
As part of its coverage, this report provides data and business planning resources for the industry.
Table of Contents
-
Chapter 1: Executive Summary and COVID-19 Developments
- Overview
- Definitions of Companion Diagnostics and Personalized Medicine Used in This Report
- Terms Used in Companion Diagnostics and Personalized Medicine
- COVID-19 CDx Test Volume Impact: Minimal Ongoing Significant Disruptions
- Biomarker Development: COVID-19 Focus
- Addressing COVID-19 with a Personalized Medicine Approach
- Scope and Methodology
- Market Summary
-
Chapter 2: Introduction to Personalized Healthcare and Companion Diagnostics
- Overview
-
Regulatory Changes
- FDA changes in CDx regulation: Shifting to Drug Classification CDx Labeling
- EU Companion Diagnostic Regulation Guidance
- The FDA and Identifying Pharmacogenetic Associations
-
Reimbursement Breakthroughs and Challenges
- Next Generation Sequencing Coverage
- CDx Approvals: United States FDA
- The Market for Targeted Therapies: Oncology
- Targeted Therapies in Development
-
Development in NGS for CDx
- Next Generation Sequencing or Massively Parallel Sequencing in Cancer Diagnostics
- The Evolving Opportunity in Japan
-
Disease Profiles in CDx Markets
- Cancer
- Cardiovascular Disease
- Selected Blood Disorders
- Autoimmune and Immunological Diseases
- Infectious Diseases
-
Chapter 3: Companion Dx Market Analysis
- Market Overview
- Biomarkers in Therapeutic Labeling
-
Companion Diagnostics in Oncology
- Market Review and Outlook
-
Companion Diagnostics in Other Diseases
- Overview
- Autoimmune Disorders
- Cardiology and Hematology
- Infectious Disease
- Human Leukocyte Antigen (HLA) and COVID-19
- Neurology
- Market Review and Outlook
-
Diagnostic Techniques
- Market Overview
- Immunohistochemistry (IHC)
- In Situ Hybridization
- Nucleic Acid Amplification Technologies
- Sequencing Technologies
- Flow Cytometry
- Microarrays
- Mass Spectrometry
- Liquid Biopsies – Circulating Tumor Cells and Circulating Tumor DNA (Cell Free DNA)
- Analysis of Gene Expression Patterns (Gene Signatures)
- Information Technology
-
Regional Market Review
- U.S. Market
- European Market
- Reimbursement in European Markets
- Japanese Market
- Chinese Market
- Rest of World Market
-
Chapter 4: Competitive Analysis
- Competitive Landscape
- Alliances, Acquisitions and Collaborations
- Competitor Analysis
- CDx Product Mix: Leading IVD Companies
-
Chapter 5: Market Participant Profiles
- Profile Scope
-
Abbott Diagnostics
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Agilent Technologies Inc./Dako
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Biocartis
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Foundation Medicine, Inc.
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Guardant Health, Inc.
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Illumina, Inc.
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Myriad Genetics, Inc.
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
NeoGenomics
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
QIAGEN N.V.
- Company Overview
- Financial Review
- Product Overview: Companion Dx
-
Roche Diagnostics
- Company Overview
- Financial Review
- Company Overview: Companion Dx
-
Thermo Fisher Scientific Inc.
- Company Overview
- Financial Review
- Product Overview: Companion Dx